What is the share price of Zenotech Laboratories Ltd (ZENOTECH) today?
The share price of ZENOTECH as on 11th July 2025 is ₹60.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Zenotech Laboratories Ltd (ZENOTECH) share?
The past returns of Zenotech Laboratories Ltd (ZENOTECH) share are- Past 1 week: -5.22%
- Past 1 month: -1.26%
- Past 3 months: -1.15%
- Past 6 months: -1.32%
- Past 1 year: -4.16%
- Past 3 years: 17.37%
- Past 5 years: 152.41%
What are the peers or stocks similar to Zenotech Laboratories Ltd (ZENOTECH)?
The peers or stocks similar to Zenotech Laboratories Ltd (ZENOTECH) include:What is the market cap of Zenotech Laboratories Ltd (ZENOTECH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Zenotech Laboratories Ltd (ZENOTECH) is ₹381.14 Cr as of 11th July 2025.What is the 52 week high and low of Zenotech Laboratories Ltd (ZENOTECH) share?
The 52-week high of Zenotech Laboratories Ltd (ZENOTECH) is ₹107.79 and the 52-week low is ₹51.What is the PE and PB ratio of Zenotech Laboratories Ltd (ZENOTECH) stock?
The P/E (price-to-earnings) ratio of Zenotech Laboratories Ltd (ZENOTECH) is 67.94. The P/B (price-to-book) ratio is 3.96.Which sector does Zenotech Laboratories Ltd (ZENOTECH) belong to?
Zenotech Laboratories Ltd (ZENOTECH) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Zenotech Laboratories Ltd (ZENOTECH) shares?
You can directly buy Zenotech Laboratories Ltd (ZENOTECH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Zenotech Laboratories Ltd
ZENOTECH Share Price
60.652.88% (-1.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ZENOTECH Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ZENOTECH Performance & Key Metrics
ZENOTECH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 68.67 | 3.96 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.59 | 6.40 | 0.79% |
ZENOTECH Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ZENOTECH Company Profile
The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves therapy areas, such as oncology and anesthesiology.
BIOCON
PE Ratio
49.05
49.05
1Y Return
5.54%
5.54%
Buy Reco %
73.33
73.33
ONESOURCE
PE Ratio
-1,270.92
-1,270.92
1Y Return
15.75%
15.75%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
95.98
95.98
1Y Return
2.29%
2.29%
Buy Reco %
66.67
66.67
ACUTAAS
PE Ratio
58.51
58.51
1Y Return
69.15%
69.15%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-298.57
-298.57
1Y Return
196.30%
196.30%
Buy Reco %
0.00
0.00
ZENOTECH Forecast
ZENOTECH Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ZENOTECH
ZENOTECH
Income
Balance Sheet
Cash Flow
Annual Normal View
ZENOTECH Income Statement
ZENOTECH Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.16 | 13.51 | 17.74 | 33.56 | 22.86 | 37.20 | 43.50 | 41.83 | 46.52 | 46.57 | ||||||||||
Raw Materials | 1.52 | 0.81 | 0.71 | 0.50 | 0.03 | 0.00 | 0.06 | 0.00 | 0.84 | 28.92 | ||||||||||
| Power & Fuel Cost | 1.94 | 4.24 | 3.68 | 3.29 | 3.12 | 3.25 | 3.79 | 2.69 | 2.71 | |||||||||||
| Employee Cost | 3.02 | 5.07 | 4.98 | 5.76 | 6.49 | 7.10 | 7.88 | 9.46 | 12.38 | |||||||||||
| Selling & Administrative Expenses | 2.93 | 3.57 | 2.21 | 1.75 | 1.62 | 1.91 | 2.00 | 2.33 | 2.85 | |||||||||||
| Operating & Other expenses | 3.24 | 5.32 | 4.97 | 5.74 | 4.80 | 6.84 | 7.99 | 9.13 | 10.09 | |||||||||||
EBITDA | -8.49 | -5.50 | 1.19 | 16.52 | 6.80 | 18.10 | 21.78 | 18.22 | 17.65 | 17.65 | ||||||||||
| Depreciation/Amortization | 3.87 | 3.90 | 4.20 | 4.85 | 6.46 | 6.97 | 7.17 | 7.09 | 6.96 | 6.97 | ||||||||||
| PBIT | -12.36 | -9.40 | -3.01 | 11.67 | 0.34 | 11.13 | 14.61 | 11.13 | 10.69 | 10.68 | ||||||||||
| Interest & Other Items | 7.50 | 2.45 | 0.12 | 0.89 | 1.55 | 1.22 | 0.11 | 0.00 | 0.00 | — | ||||||||||
| PBT | -19.86 | -11.85 | -3.13 | 10.78 | -1.21 | 9.91 | 14.50 | 11.13 | 10.69 | 10.68 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27 | 2.92 | 2.84 | 5.08 | 5.13 | ||||||||||
| Net Income | -19.86 | -11.85 | -3.13 | 10.78 | -1.21 | 22.18 | 11.58 | 8.29 | 5.61 | 5.55 | ||||||||||
| EPS | -5.47 | -2.44 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.36 | 0.92 | 0.91 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ZENOTECH Company Updates
ZENOTECH Stock Peers
ZENOTECH Past Performance & Peer Comparison
ZENOTECH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation-basic on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Zenotech Laboratories Ltd | 67.94 | 3.96 | — |
| Biocon Ltd | 49.05 | 1.97 | 0.30% |
| Onesource Specialty Pharma Ltd | -1,270.92 | 57.68 | — |
| Sai Life Sciences Ltd | 95.98 | 16.75 | — |
ZENOTECH Stock Price Comparison
Compare ZENOTECH with any stock or ETFCompare ZENOTECH with any stock or ETF
ZENOTECH
ZENOTECH Holdings
ZENOTECH Shareholdings
ZENOTECH Promoter Holdings Trend
ZENOTECH Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ZENOTECH Institutional Holdings Trend
ZENOTECH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ZENOTECH Shareholding Pattern
ZENOTECH Shareholding Pattern
ZENOTECH Shareholding History
ZENOTECH Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ZENOTECH stock
smallcases containing ZENOTECH stock
Looks like this stock is not in any smallcase yet.
ZENOTECH Events
ZENOTECH Events
ZENOTECH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ZENOTECH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ZENOTECH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ZENOTECH has not given any dividends in last 5 years
ZENOTECH Dividends
ZENOTECH Dividends
Hmm, looks like data is unavailable here. Please come back after some timeZENOTECH Stock News & Opinions
ZENOTECH Stock News & Opinions
Articles & Videos
Earnings
Zenotech Laboratories standalone net profit rises 86.36% in the March 2025 quarter
Net profit of Zenotech Laboratories rose 86.36% to Rs 1.23 crore in the quarter ended March 2025 as against Rs 0.66 crore during the previous quarter ended March 2024. Sales rose 37.33% to Rs 11.11 crore in the quarter ended March 2025 as against Rs 8.09 crore during the previous quarter ended March 2024. For the full year,net profit declined 32.41% to Rs 5.61 crore in the year ended March 2025 as against Rs 8.30 crore during the previous year ended March 2024. Sales rose 6.04% to Rs 38.98 crore in the year ended March 2025 as against Rs 36.76 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales11.118.09 37 38.9836.76 6 OPM %40.2334.24 -36.3846.87 - PBDT4.963.10 60 15.7318.23 -14 PBT3.231.37 136 8.7711.14 -21 NP1.230.66 86 5.618.30 -32 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Zenotech Laboratories to conduct board meeting
Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 25 April 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Zenotech Laboratories standalone net profit declines 49.70% in the December 2024 quarter
Net profit of Zenotech Laboratories declined 49.70% to Rs 1.69 crore in the quarter ended December 2024 as against Rs 3.36 crore during the previous quarter ended December 2023. Sales rose 3.02% to Rs 10.22 crore in the quarter ended December 2024 as against Rs 9.92 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales10.229.92 3 OPM %37.8753.02 - PBDT4.255.54 -23 PBT2.493.80 -34 NP1.693.36 -50 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Zenotech Laboratories schedules board meeting
Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Zenotech Laboratories standalone net profit declines 52.30% in the September 2024 quarter
Net profit of Zenotech Laboratories declined 52.30% to Rs 1.35 crore in the quarter ended September 2024 as against Rs 2.83 crore during the previous quarter ended September 2023. Sales declined 16.75% to Rs 8.75 crore in the quarter ended September 2024 as against Rs 10.51 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales8.7510.51 -17 OPM %27.5452.43 - PBDT2.755.70 -52 PBT1.003.89 -74 NP1.352.83 -52 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Zenotech Laboratories to discuss results
Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Zenotech Laboratories schedules AGM
Zenotech Laboratories announced that the 35th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Zenotech Laboratories standalone net profit declines 10.42% in the June 2024 quarter
11 months agoBusiness Standard
Earnings
Zenotech Laboratories standalone net profit declines 10.42% in the June 2024 quarter
Net profit of Zenotech Laboratories declined 10.42% to Rs 1.29 crore in the quarter ended June 2024 as against Rs 1.44 crore during the previous quarter ended June 2023. Sales rose 7.89% to Rs 8.89 crore in the quarter ended June 2024 as against Rs 8.24 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales8.898.24 8 OPM %38.7044.42 - PBDT3.783.86 -2 PBT2.052.06 0 NP1.291.44 -10 Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Zenotech Laboratories schedules board meeting
Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.75%, vs industry avg of 21.18%
Over the last 5 years, market share decreased from 0.4% to 0.21%
Over the last 5 years, net income has grown at a yearly rate of -12.25%, vs industry avg of 20.36%